Last reviewed · How we verify
Rituximab infusion
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.
At a glance
| Generic name | Rituximab infusion |
|---|---|
| Also known as | Mabthera, Rituxan |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell destruction including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune and malignant B cell populations.
Approved indications
- Non-Hodgkin's lymphoma (B-cell)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Common side effects
- Infusion reactions
- Neutropenia
- Thrombocytopenia
- Anemia
- Infections
- Fatigue
- Fever
- Chills
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
- Rituximab for Anti-cytokine Autoantibody-Associated Diseases (PHASE1)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab infusion CI brief — competitive landscape report
- Rituximab infusion updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Saint Etienne portfolio CI